Novo Nordisk in short
Novo Nordisk sales totalled DKK 78.026 million (EUR 10.457 million) in 2012. With headquarters in Denmark, Novo Nordisk employs approximately 34.286 full-time employees in 75 countries, and markets its products in 181 countries.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Triple bottom line focus
Novo Nordisk is committed to developing its business towards ecological, social and economic sustainability. This commitment is demonstrated through its values and its environmental and social responsibility policies.
Stock exchange listings
Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.